MiR-133b ameliorates axon degeneration induced by MPP+ via targeting RhoA

Neuroscience

Volumn 325, Issue , 2016, Pages 39-49

  Niu, M ^a   Xu, R ^a   Wang, J ^a   Hou, B ^a   Xie, A ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Alpha synuclein; Axon degeneration; MiR 133b; Parkinson's disease; RhoA

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; MICRORNA; MICRORNA 133B; PROTEIN BAX; PROTEIN BCL 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; MIRN133 MICRORNA, RAT; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; APOPTOSIS; AXON; CELL CULTURE; DRUG EFFECTS; METABOLISM; NEURITE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; AXONS; CELLS, CULTURED; DOPAMINERGIC NEURONS; MICRORNAS; NEURITES; PARKINSON DISEASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84963635530     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.03.042     Document Type: Article

References (59)

1. Asci R., Vallefuoco F., Andolfo I., Bruno M., De Falco L., Iolascon A. Trasferrin receptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with MPP(+) as Parkinson's disease cellular model. Neurosci Res 2013, 77:121-127.
2. Barcia C., Ros C.M., Annese V., Carrillo-de Sauvage M.A., Ros-Bernal F., Gomez A., Yuste J.E., Campuzano C.M., de Pablos V., Fernandez-Villalba E., Herrero M.T. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep 2012, 2:809.
3. Bartel D.P., Chen C.Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004, 5:396-400.
4. Bilen J., Liu N., Burnett B.G., Pittman R.N., Bonini N.M. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell 2006, 24:157-163.
5. Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis V.R. Oxidative stress and Parkinson's disease. Front Neuroanat 2015, 9:91.
6. Boada J., Cutillas B., Roig T., Bermudez J., Ambrosio S. MPP(+)-induced mitochondrial dysfunction is potentiated by dopamine. Biochem Biophys Res Commun 2000, 268:916-920.
7. Borrajo A., Rodriguez-Perez A.I., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology 2014, 85:1-8.
8. Bostjancic E., Jerse M., Glavac D., Zidar N. MiR-1, miR-133a/b, and miR-208a in human fetal hearts correlate to the apoptotic and proliferation markers. Exp Biol Med 2015, 240:211-219.
9. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2013, 246:72-83.
10. Cheng H.C., Kim S.R., Oo T.F., Kareva T., Yarygina O., Rzhetskaya M., Wang C., During M., Talloczy Z., Tanaka K., Komatsu M., Kobayashi K., Okano H., Kholodilov N., Burke R.E. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 2011, 31:2125-2135.
11. Cui W., Li W., Han R., Mak S., Zhang H., Hu S., Rong J., Han Y. PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP+-induced neuronal apoptosis. Neurochem Int 2011, 59:945-953.
12. Eacker S.M., Dawson T.M., Dawson V.L. Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 2009, 10:837-841.
13. Eriksen J.L., Dawson T.M., Dickson D.W., Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 2003, 40:453-456.
14. Ferri A., Sanes J.R., Coleman M.P., Cunningham J.M., Kato A.C. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol: CB 2003, 13:669-673.
15. Fragkouli A., Doxakis E. MiR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci 2014, 8:182.
16. Gartel A.L., Kandel E.S. miRNAs: little known mediators of oncogenesis. Semin Cancer Biol 2008, 18:103-110.
17. Gomez-Santos C., Ferrer I., Reiriz J., Vinals F., Barrachina M., Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 2002, 935:32-39.
18. Guo L., Bai H., Zou D., Hong T., Liu J., Huang J., He P., Zhou Q., He J. The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J Exp Clin Cancer Res: CR 2014, 33:99.
19. Hashimoto R., Yu J., Koizumi H., Ouchi Y., Okabe T. Ginsenoside Rb1 Prevents MPP(+)-Induced Apoptosis in PC12 Cells by Stimulating Estrogen Receptors with Consequent Activation of ERK1/2, Akt and Inhibition of SAPK/JNK, p38 MAPK. Evid-based Complement Alternat Med: eCAM 2012, 2012:693717.
20. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., Johannessen J.N. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991, 40:133-158.
21. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4.
22. Jethva P.N., Kardani J.R., Roy I. Modulation of alpha-synuclein aggregation by dopamine in the presence of MPTP and its metabolite. FEBS J 2011, 278:1688-1698.
23. Junyent F., Alvira D., Yeste-Velasco M., de la Torre A.V., Beas-Zarate C., Sureda F.X., Folch J., Pallas M., Camins A., Verdaguer E. Prosurvival role of JAK/STAT and Akt signaling pathways in MPP+-induced apoptosis in neurons. Neurochem Int 2010, 57:774-782.
24. Kadota T., Yamaai T., Saito Y., Akita Y., Kawashima S., Moroi K., Inagaki N., Kadota K. Expression of dopamine transporter at the tips of growing neurites of PC12 cells. J Histochem Cytochem 1996, 44:989-996.
25. Kalivendi S.V., Cunningham S., Kotamraju S., Joseph J., Hillard C.J., Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 2004, 279:15240-15247.
26. Kanagaraj N., Beiping H., Dheen S.T., Tay S.S. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Neuroscience 2014, 272:167-179.
27. Katoh H., Aoki J., Ichikawa A., Negishi M. P160 RhoA-binding kinase ROKalpha induces neurite retraction. J Biol Chem 1998, 273:2489-2492.
28. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
29. Kosik K.S. The neuronal microRNA system. Nat Rev Neurosci 2006, 7:911-920.
30. Labandeira-Garcia J.L., Rodriguez-Perez A.I., Villar-Cheda B., Borrajo A., Dominguez-Meijide A., Guerra M.J. Rho kinase and dopaminergic degeneration: a promising therapeutic target for Parkinson's disease. Neuroscientist 2014.
31. Lim K.L., Dawson V.L., Dawson T.M. The cast of molecular characters in Parkinson's disease: felons, conspirators, and suspects. Ann N Y Acad Sci 2003, 991:80-92.
32. Liu N.K., Wang X.F., Lu Q.B., Xu X.M. Altered microRNA expression following traumatic spinal cord injury. Exp Neurol 2009, 219:424-429.
33. Liu Y.Y., Yang X.Y., Li Z., Liu Z.L., Cheng D., Wang Y., Wen X.J., Hu J.Y., Liu J., Wang L.M., Wang H.J. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease. CNS Neurosci Ther 2014, 20:76-85.
34. Lu X.C., Zheng J.Y., Tang L.J., Huang B.S., Li K., Tao Y., Yu W., Zhu R.L., Li S., Li L.X. MiR-133b Promotes neurite outgrowth by targeting RhoA expression. Cell Physiol Biochem 2015, 35:246-258.
35. Lunn E.R., Perry V.H., Brown M.C., Rosen H., Gordon S. Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur J Neurosci 1989, 1:27-33.
36. Malagelada C., Jin Z.H., Greene L.A. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008, 28:14363-14371.
37. Martins M., Rosa A., Guedes L.C., Fonseca B.V., Gotovac K., Violante S., Mestre T., Coelho M., Rosa M.M., Martin E.R., Vance J.M., Outeiro T.F., Wang L., Borovecki F., Ferreira J.J., Oliveira S.A. Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS ONE 2011, 6:e25443.
38. Minones-Moyano E., Porta S., Escaramis G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X., Marti E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011, 20:3067-3078.
39. Moon H.E., Paek S.H. Mitochondrial dysfunction in Parkinson's disease. Exp Neurobiol 2015, 24:103-116.
40. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002, 58:179-185.
41. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
42. Qin W., Dong P., Ma C., Mitchelson K., Deng T., Zhang L., Sun Y., Feng X., Ding Y., Lu X., He J., Wen H., Cheng J. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 2012, 31:4067-4075.
43. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006, 103:18757-18762.
44. Shafer T.J., Atchison W.D. Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies. Neurotoxicology 1991, 12:473-492.
45. Shi J., Wei L. Rho kinase in the regulation of cell death and survival. Archivum immunologiae et therapiae experimentalis 2007, 55:61-75.
46. Shimoda K., Sauve Y., Marini A., Schwartz J.P., Commissiong J.W. A high percentage yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture. Brain Res 1992, 586:319-331.
47. Thomas B., Beal M.F. Parkinson's disease. Hum Mol Genet 2007, R183-R194. 16 Spec No. 2.
48. Tolleson C.M., Fang J.Y. Advances in the mechanisms of Parkinson's disease. Discovery Med 2013, 15:61-66.
49. Tonges L., Frank T., Tatenhorst L., Saal K.A., Koch J.C., Szego E.M., Bahr M., Weishaupt J.H., Lingor P. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 2012, 135:3355-3370.
50. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000, 74:721-729.
51. Villar-Cheda B., Dominguez-Meijide A., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 2012, 47:268-279.
52. Wen D., Li S., Ji F., Cao H., Jiang W., Zhu J., Fang X. MiR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer. Tumour Biol 2013, 34:793-803.
53. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl 1):S1-S58.
54. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100:6145-6150.
55. Wu F., Poon W.S., Lu G., Wang A., Meng H., Feng L., Li Z., Liu S. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells. Brain Res 2009, 1292:173-179.
56. Xin H., Li Y., Liu Z., Wang X., Shang X., Cui Y., Zhang Z.G., Chopp M. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells 2013, 31:2737-2746.
57. Yu Y.M., Gibbs K.M., Davila J., Campbell N., Sung S., Todorova T.I., Otsuka S., Sabaawy H.E., Hart R.P., Schachner M. MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish. Eur J Neurosci 2011, 33:1587-1597.
58. Zhao N., Jin L., Fei G., Zheng Z., Zhong C. Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease. Parkins Relat Disord 2014, 20:1177-1180.
59. Zhou Z., Kim J., Insolera R., Peng X., Fink D.J., Mata M. Rho GTPase regulation of alpha-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease. Mol Cell Neurosci 2011, 48:29-37.